JO
LAB icon

John Overdeck’s Standard BioTools LAB Stock Holding History

John Overdeck’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-286,941
Closed -$502K – 3368
2024
Q4 		$502K Sell
286,941
-27,300
-9% -$50.9K ﹤0.01% 2540
2024
Q3 		$606K Sell
314,241
-89,288
-22% -$175K ﹤0.01% 2373
2024
Q2 		$714K Sell
403,529
-243,411
-38% -$595K ﹤0.01% 2179
2024
Q1 		$1.75M Buy
646,940
+490,337
+313% +$1.18M ﹤0.01% 1577
2023
Q4 		$346K Buy
+156,603
New +$334K ﹤0.01% 2636
2021
Q4 		– Sell
-171,457
Closed -$1.13M – 4589
2021
Q3 		$1.13M Buy
171,457
+147,209
+607% +$968K ﹤0.01% 2506
2021
Q2 		$149K Sell
24,248
-240,120
-91% -$1.28M ﹤0.01% 3848
2021
Q1 		$1.2M Sell
264,368
-325,869
-55% -$1.79M ﹤0.01% 2148
2020
Q4 		$3.54M Buy
590,237
+525,144
+807% +$3.45M 0.01% 1128
2020
Q3 		$484K Sell
65,093
-562,376
-90% -$3.88M ﹤0.01% 2275
2020
Q2 		$2.52M Buy
627,469
+159,663
+34% +$556K 0.01% 982
2020
Q1 		$1.19M Sell
467,806
-138,545
-23% -$455K 0.01% 1295
2019
Q4 		$2.11M Sell
606,351
-222,059
-27% -$781K 0.01% 1544
2019
Q3 		$3.84M Buy
828,410
+194,525
+31% +$1.53M 0.01% 1011
2019
Q2 		$7.81M Sell
633,885
-236,795
-27% -$3.02M 0.03% 702
2019
Q1 		$11.6M Buy
870,680
+384,880
+79% +$4.06M 0.04% 603
2018
Q4 		$4.19M Buy
485,800
+255,244
+111% +$1.99M 0.02% 887
2018
Q3 		$1.73M Buy
230,556
+77,549
+51% +$551K ﹤0.01% 1583
2018
Q2 		$912K Buy
153,007
+11,731
+8% +$66.9K ﹤0.01% 2214
2018
Q1 		$825K Buy
141,276
+24,669
+21% +$162K ﹤0.01% 2132
2017
Q4 		$687K Buy
116,607
+83,330
+250% +$456K ﹤0.01% 2220
2017
Q3 		$168K Buy
+33,277
New +$140K ﹤0.01% 2617
2014
Q1 		– Sell
-28,189
Closed -$1.08M – 2138
2013
Q4 		$1.08M Sell
28,189
-71,523
-72% -$2.11M 0.01% 1294
2013
Q3 		$2.19M Buy
99,712
+78,836
+378% +$1.55M 0.01% 754
2013
Q2 		$364K Buy
+20,876
New +$366K ﹤0.01% 1552

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's LAB Position: Q1 2025 in Review

John Overdeck sold out of Standard BioTools (LAB) in Q1 2025, closing a stake of 286,941 shares — an estimated $502K sold.

John Overdeck first reported a position in LAB in Q2 2013 and held it in 25 quarters. The position peaked at $11.6M in Q1 2019. 145 funds tracked by Wall St. Rank hold LAB as of Q1 2025.

  • John Overdeck reported no remaining Standard BioTools position as of Q1 2025 after selling out during the quarter.
  • John Overdeck sold 286,941 Standard BioTools shares in Q1 2025, an estimated $502K.
  • John Overdeck first reported a position in Standard BioTools in Q2 2013 and held it in 25 quarters.
  • John Overdeck's Standard BioTools position peaked at $11.6M in Q1 2019.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2025.

Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.